Clinical Trial Update: Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial evaluating olverembatinib as maintenance or preemptive therapy after allogeneic hematopoietic stem cell transplant in Philadelp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• Olverembatinib (Olverembatinib)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), HSCT | Phase 2 | Status: NOT_YET_RECRUITING